Onco-Hematology and Immunotherapy

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 1304

Special Issue Editors


E-Mail Website
Guest Editor
Unité de Neurobiologie des Canaux Ioniques et de la Synapse, Marseille, France
Interests: leukemia; molecular biology; oncology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
AP-HM Assistance Publique—Hôpitaux de Marseille, Marseille, France
Interests: cancer biology; molecular biology; T lymphocytes; immune response; cytokines; next generation sequencing; gene regulation; lymphoma; transcriptomics; flow cytometry

Special Issue Information

Dear Colleagues,

Leukemias and lymphomas are deadly cancers that mainly affect adults, but leukemias are the second most frequent cancer among children. Today, adult and children with different diseases are treated with different protocols.

New treatments are warranted, and, recently, immunotherapy has appeared as an efficient new tool. Cancers (in general) and onco-hematology (in particular) escape the normal immune control. So, on one side, a better understanding of this phenomenon is required; on the other side, immunotherapy in leukemias aims to boost the immune system in order to fight against cancer cells (leukemias or lymphomas in onco-hematology). The main tools are T cells and antibodies, but trials are also in progress with immune check point inhibitors, leukemia and lymphoma vaccines, and immunomodulators. Allograft in chronic myeloid leukemia is certainly the first example, followed by T cell infusions after allogeneic bone marrow transplantation. The main problems are to understand the normal immune control and its escape in the case of leukemia and lymphomas, as well as to identify the right patients who will benefit from these treatments. So, it is clearly a vast area of research and is also a very promising new tool for precision medicine which could be associated with new or hold drugs.

Prof. Dr. Jean Gabert
Prof. Dr. Régis T. Costello
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • onco-hematology
  • CAR T cells
  • NK cells
  • immune system
  • immune cells
  • leukemias
  • lymphomas

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1156 KiB  
Article
Outcome of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma after Different Numbers of Salvage Regimens
by Jacopo Mariotti, Francesca Ricci, Laura Giordano, Daniela Taurino, Barbara Sarina, Chiara De Philippis, Daniele Mannina, Carmelo Carlo-Stella, Stefania Bramanti and Armando Santoro
Cells 2024, 13(2), 118; https://doi.org/10.3390/cells13020118 - 9 Jan 2024
Viewed by 1081
Abstract
The introduction of novel drugs (PD-1 inhibitors and/or brentuximab vedotin) into salvage regimens has improved the response rate and the outcome of patients with relapsed/refractory Hodgkin lymphoma. However, the impact of new drugs on the outcome has not been adequately investigated so [...] Read more.
The introduction of novel drugs (PD-1 inhibitors and/or brentuximab vedotin) into salvage regimens has improved the response rate and the outcome of patients with relapsed/refractory Hodgkin lymphoma. However, the impact of new drugs on the outcome has not been adequately investigated so far. We retrospectively analyzed 42 consecutive patients treated at our institution with high-dose chemotherapy/autologous stem cell transplantation after either one standard chemotherapy represented by BEGEV (n = 28) or >1 salvage therapy (ST) comprising novel drugs (n = 14). With a median follow-up of 24 months, the 2-year cumulative incidence of relapse was similar between the two cohorts: 26% for 1 ST and 18% for >1 ST (p = 0.822). Consistently, overall survival and progression-free survival did not differ among the two groups: 3-year overall survival was 91% and 89% (p = 0.731), respectively, and 3-year progression-free survival was 74% and 83% (p = 0.822) for only one and more than one salvage regimens, respectively. Of note, the post-transplant side effects and engraftment rates were similar between the 1 ST and >1 ST cohorts. In conclusion, consolidation with high-dose chemotherapy/autologous stem cell transplantation is a safe and curative option, even for patients achieving disease response after more than one rescue line of therapy. Full article
(This article belongs to the Special Issue Onco-Hematology and Immunotherapy)
Show Figures

Graphical abstract

Back to TopTop